Genocea Biosciences (GNCA) Tops Q4 EPS by 1c

Genocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).

Genocea’s existing cash is sufficient to support our current operations into Q3 2022, however we have strategic plans to extend our operations into 2023.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• UBS Reiterates Buy Rating on Cheniere Energy (LNG)
• Profound Medical names Richard Fabian as president